Common metabolic features of hypertension and type 2 diabetes

被引:18
|
作者
Usui, Isao [1 ]
机构
[1] Dokkyo Med Univ, Dept Endocrinol & Metab, Tochigi, Japan
关键词
Hypertension; Type; 2; diabetes; Obesity; Insulin resistance; Sympathetic nerve; CHRONIC KIDNEY-DISEASE; SKELETAL-MUSCLE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; RISK; VASODILATION; MELLITUS; GLUCOSE; HYPERINSULINEMIA; ACTIVATION;
D O I
10.1038/s41440-023-01233-x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Hypertension and type 2 diabetes frequently coexist, suggesting that the two diseases have common pathophysiological bases. This review describes the pathophysiological mechanisms of how type 2 diabetes is frequently associated with hypertension. Multiple common factors mediate between both diseases. Factors that induce both type 2 diabetes and hypertension include obesity-induced hyperinsulinemia, activation of the sympathetic nervous system, chronic inflammation, and changes in adipokines. Vascular complications resulting from type 2 diabetes and hypertension include endothelial dysfunction, vasodilation/constriction dysfunction of peripheral vessels and increased peripheral vascular resistance, arteriosclerosis, and chronic kidney disease. While many of these vascular complications are caused by hypertension, they also exacerbate the pathology of hypertension. In addition, insulin resistance in the vasculature blunts insulin-induced vasodilation and blood flow to skeletal muscle, which contributes to impaired glucose uptake to skeletal muscle and glucose intolerance. In obese and insulin-resistant patients, increase in the circulating fluid volume forms the major pathophysiology of elevated blood pressure. On the other hand, in non-obese and/or insulin-deficient patients, especially those in the middle-or later stages of diabetes, peripheral vascular resistance is the major pathophysiology of hypertension.
引用
收藏
页码:1227 / 1233
页数:7
相关论文
共 50 条
  • [31] Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study)
    Buscemi, Silvio
    Buscemi, Carola
    Borzi, Antonio Maria
    Cosentino, Loretta
    Rosafio, Giuseppe
    Randazzo, Cristiana
    Colomba, Daniela
    Di Raimondo, Domenico
    Pluchinotta, Francesca Romana
    Parrinello, Gaspare
    METABOLIC SYNDROME AND RELATED DISORDERS, 2020, 18 (02) : 110 - 118
  • [32] Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
    Esser, Nathalie
    Legrand-Poels, Sylvie
    Piette, Jacques
    Scheen, Andre J.
    Paquot, Nicolas
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 105 (02) : 141 - 150
  • [33] Metabolic index in Mayas: association with hypercholesterolemia in patients with type 2 diabetes
    Lara-Riegos, Julio
    Ramirez-Camacho, Mario
    Torres-Romero, Julio
    Arana-Argaez, Victor
    Cervera-Cetina, Antonio
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2018, 52 (02): : 195 - 203
  • [34] Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension
    Arao, Tadashi
    Okada, Yosuke
    Mori, Hiroko
    Nishida, Keiko
    Tanaka, Yoshiya
    ENDOCRINE JOURNAL, 2013, 60 (05) : 563 - 570
  • [35] Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift
    Nolan, Christopher J.
    Prentki, Marc
    DIABETES & VASCULAR DISEASE RESEARCH, 2019, 16 (02) : 118 - 127
  • [36] Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial
    Mobini, Reza
    Tremaroli, Valentina
    Stahlman, Marcus
    Karlsson, Fredrik
    Levin, Max
    Ljungberg, Maria
    Sohlin, Maja
    Forslund, Helene Berteus
    Perkins, Rosie
    Backhed, Fredrik
    Jansson, Per-Anders
    DIABETES OBESITY & METABOLISM, 2017, 19 (04) : 579 - 589
  • [37] Body Composition and the Components of Metabolic Syndrome in Type 2 Diabetes: The Roles of Disease Duration and Glycemic Control
    Abulmeaty, Mahmoud M. A.
    Aljuraiban, Ghadeer S.
    Alaidarous, Thuraya A.
    Alkahtani, Noura M.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 1051 - 1059
  • [38] Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes:: the Skaraborg Hypertension and Diabetes Project
    Östgren, CJ
    Lindblad, U
    Bog-Hansen, E
    Ranstam, J
    Melander, A
    Råstam, L
    DIABETES OBESITY & METABOLISM, 1999, 1 (02) : 105 - 112
  • [39] Is uric acid an indicator of metabolic syndrome in the first-degree relatives of patients with type 2 diabetes?
    Salehidoost, Rezvan
    Aminorroaya, Ashraf
    Zare, Maryam
    Amini, Massoud
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2012, 17 (11): : 1005 - 1010
  • [40] Association between surrogate indicators of insulin resistance and risk of type 2 diabetes combined with hypertension among Chinese adults: two independent cohort studies
    Dong, Jing
    Liu, Yu-Hong
    Lu, Ya-Ke
    Hu, Li-Kun
    Chen, Ning
    Ma, Lin-Lin
    Chu, Xi
    Yan, Yu-Xiang
    NUTRITION & METABOLISM, 2022, 19 (01)